VIOXX written off--and what next? COX-2 inhibitors and cardiovascular diseases
Jerie, P.
Casopis Lekaru Ceskych 144(1): 4
2005
ISSN/ISBN: 0008-7335 PMID: 15789774 Document Number: 588662
Document emailed within 1 workday
Related Documents
Brune, K.; Zacher, J. 2004: Cardiovascular risk: a class effect of coxibs? how to manage patients taking Vioxx? MMW Fortschritte der Medizin 146(42): 10; 12Weser, C.; Klessen, D. 1978: Strategy for the control of cardiovascular diseases in a metropolis (demonstrated by the Berlin concept of a unified system of care for patients with cardiovascular diseases) Zeitschrift für Arztliche Fortbildung 72(20): 967-971
1999: Canadian Cardiovascular Society 1998 Consensus Conference on the Prevention of Cardiovascular Diseases: The Role of the Cardiovascular Specialist Canadian Journal of Cardiology 15 Suppl G: 1g
Boulos, G. 2001: Written information for treating minor illness. Patients find printed advice written with easy-to-find format helpful Bmj 323(7311): 517
Jobin, F. 1976: Blood platelets and cardiovascular diseases. III. Diseases with increased platelet consumption and vascular diseases L'Union Medicale du Canada 105(5): 756-766
McManus, B.M.; Wilson, J.E.; Struve, L.C. 1993: Manpower deficiencies in cardiovascular pathology. Implications for medical care of cardiovascular diseases Archives of Pathology and Laboratory Medicine 117(6): 584-588
Makar, O.; Siabrenko, G. 2018: Influence of Physical Activity on Cardiovascular System and Prevention of Cardiovascular Diseases (Review) Georgian Medical News 2018(285): 69-74
Chopeĭ, I.V.; Rosul, M.M.; Hechko, M.M.; Chubirko, K.I.; Korabel'shchykova, M.O.; Ivan'o, N.V. 2014: Cardiovascular continuum: the role of the family doctor in prevention of cardiovascular diseases Wiadomosci Lekarskie 67(2 Pt 2): 243-247
Gao, J.; Liang, X.; Shi, J.; Huang, Z.; Wei, X.; Li, H.; Lin, L.; Xing, A.; Du, X.; Wu, S. 2014: Impact of ideal cardiovascular health behaviors and factors on resting heart rate in individuals without cardiovascular diseases Zhonghua Xin Xue Guan Bing Za Zhi 42(9): 778-783
Idänpään-Heikkilä, J.E.; Klaukka, T. 2004: Rofecoxib (Vioxx) has been withdrawn, what next? Duodecim; Laaketieteellinen Aikakauskirja 120(21): 2489-2490
Huo, Y.; Li, X.Y. 2018: Deepen our thoughts on the prevention of cardiovascular disease and actively contribute to the earlier appearance of the turning point noting the reduced prevalence of cardiovascular diseases Zhonghua Xin Xue Guan Bing Za Zhi 46(1): 3-6
Hawker, G.A.; Katz, J.N.; Solomon, D.H. 2006: The patient's perspective on the recall of Vioxx Journal of Rheumatology 33(6): 1082-1088
Wong, M.; Chowienczyk, P.; Kirkham, B. 2005: Cardiovascular issues of COX-2 inhibitors and NSAIDs Australian Family Physician 34(11): 945-948
Lampton, L. 2004: Vioxx, pharmacovigilance, flu vaccine, and the "prepared mind" Journal of the Mississippi State Medical Association 45(11): 333-335
2016: NSAIDs and serious cardiovascular disorders: especially cox-2 inhibitors and diclofenac Prescrire International 25(167): 14-16
Scheen, A.J. 2000: Pharma-clinics. The drug of the month. Rofecoxib (Vioxx) Revue Medicale de Liege 55(7): 751-753
Wallentin, L. 2005: Insights and views about cardiovascular safety of COX2 inhibitors Lakartidningen 102(9): 666; 668, 671
Pellizzer, A.M.; Krum, H. 1996: ACE inhibitors in cardiovascular disease. which patient? which drug? which dose? Australian Family Physician 25(7): 1067-1069; 1072-3; 1076-1077
Doyle, J.C.; Mottram, D.R.; Stubbs, H. 1998: Prescribing of ACE inhibitors for cardiovascular disorders in general practice Journal of Clinical Pharmacy and Therapeutics 23(2): 133-136
Tuomilehto, J.; Kuulasmaa, K.; Torppa, J. 1987: WHO MONICA Project: geographic variation in mortality from cardiovascular diseases. Baseline data on selected population characteristics and cardiovascular mortality World Health Statistics Quarterly. Rapport Trimestriel de Statistiques Sanitaires Mondiales 40(2): 171-184